

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,915	12/23/2004	Kiichiro Yano	053466-0391	7057
22428 7	590 12/30/2005		EXAMINER	
FOLEY AND LARDNER LLP			CLARK, AMY LYNN	
SUITE 500 3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1655	

DATE MAILED: 12/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)			
Office Action Summary		10/518,915	YANO ET AL.			
		Examiner	Art Unit			
		Amy L. Clark	1655			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHO WHIC - Exten after 9 - If NO - Failur Any ro	DRTENED STATUTORY PERIOD FOR REPLY HEVER IS LONGER, FROM THE MAILING DASIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
<ol> <li>Responsive to communication(s) filed on <u>23 December 2004</u>.</li> <li>This action is FINAL. 2b) ☐ This action is non-final.</li> <li>Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213.</li> </ol>						
Dispositi	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) <u>1-4</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) <u>1-4</u> is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or					
Application	on Papers					
10) 🖾 -	The specification is objected to by the Examine The drawing(s) filed on <u>23 December 2004</u> is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	re: a) accepted or b) object drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).			
Priority u	nder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2) Notice	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date <u>07/05/2005</u> .	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:				

Application/Control Number: 10/518,915 Page 2

Art Unit: 1655

## **DETAILED ACTION**

## **Drawings**

The drawings are objected to because a black line appears through each drawing. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Application/Control Number: 10/518,915

Art Unit: 1655

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3 are rejected under 35 U.S.C. 102(a) as being anticipated by Deckers et al. (A).

Applicant claims an angiogenesis inhibiting and anti-aging preparation, which prevents aging, characterized by comprising one or a plurality of crude drugs selected from the group consisting of extracts of da zao (*Zizyphus jujuba Miller var. inermis Rehder*), ginseng (*Panax ginseng C. A. Meyer*), roman chamomile (*Anthemis nobilis Linne*), chlorella (*Chlorella vulgaris Chick*), celery (*Apium graveolens Linne*), parsley or (*Petroselinum sativum Hoffman*), coicis semen (*Coix lacryma-jobi Linne var. ma-yuen Stapf*) and silk (*bombyx mori*).

Deckers teaches a composition containing anti-aging and anti-wrinkle actives (See column 20, lines 9-12) and angiogenesis blocking agents (See column 21, lines 19) comprising of ginseng extract (See column 23, line 6).

Therefore, the reference anticipates the claimed subject matter.

Claims 2 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Tominaga (B).

Tominaga teaches an anti-aging preparation for cutaneous application which prevents wrinkles (See abstract) comprising of ginseng extract and coicis semen extract (*Coix lacryma-jobi*, See column 6, lines 55-56 and 59-61), which is synonymous with *Coix lacryma-jobi Linne var. ma-yuen Stapf*.

Art Unit: 1655

Therefore, the reference anticipates the claimed subject matter.

Claims 2 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Alaluf et al. (C).

Applicant claims a method for inhibiting aging, comprising administering an antiaging preparation, which prevents aging, characterized by comprising one or a plurality of crude drugs selected from the group consisting of extracts of da zao (*Zizyphus jujuba Miller var. inermis Rehder*), ginseng (*Panax ginseng C. A. Meyer*), roman chamomile (*Anthemis nobilis Linne*), chlorella (*Chlorella vulgaris Chick*), celery (*Apium graveolens Linne*), parsley or (*Petroselinum sativum Hoffman*), coicis semen (*Coix lacryma-jobi Linne var. ma-yuen Stapf*) and silk (*bombyx mori*).

Alauf teaches a cosmetic method for treating/preventing aged, wrinkled (or wrinkling) or photodamaged skin (See abstract, column 2, lines 9-17 and Claim 1), comprising of parsley seed oil and celery seed oil (See column 3, lines 4-8).

Therefore, the reference anticipates the claimed subject matter.

\* Applicant is advised that the <u>cited U.S.</u> patents and patent application publications are available for download via the Office's PAIR. As an alternate source, <u>all U.S.</u> patents and patent application publications are available on the USPTO web site (<u>www.uspto.gov</u>), from the Office of Public Records and from commercial sources. Should you receive inquiries about the use of the Office's PAIR system, applicants may be referred to the Electronic Business Center (EBC) at <a href="http://www.uspto.gov/ebc/index.html">http://www.uspto.gov/ebc/index.html</a> or 1-866-217-9197.

Application/Control Number: 10/518,915 Page 5

Art Unit: 1655

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy L. Clark whose telephone number is (571) 272-1310. The examiner can normally be reached on 8:30am - 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amy L. Clark AU 1655

Amy L. Clark December 21, 2005

> Jenga McCeleg TERRY MCKELVEY PRIMARY EXAMINER